TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03571230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two sensitive antibiotics(amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline)
Description: Patients will receive a 10-day triple therapy for the H.pylori eradication. The regimen contains one PPI and two sensitive antibiotics determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole, levofloxacin, furazolidone and tetracycline will be evaluated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)
Description: Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.

Intervention type: DRUG
Group type: OTHER
Intervention: two antibiotics based on personal medication history(amoxicillin,clarithromycin,furazolidone)
Description: Patients will receive a 14-day bismuth-based quadruple therapy for the H.pylori eradication. The regimen contains one PPI, Colloidal Bismuth Pectin and two antibiotics based on personal medication history. If the patient has taken clarithromycin, roxithromycin and azithromycin for less than 2 weeks before, he will be treated with amoxicillin and clarithromycin. Otherwise, he will be treated with amoxicillin and furazolidone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one proton pump inhibitor(PPI)
Description: All the patients need this drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: one proton pump inhibitor(PPI)
Description: All the patients need this drug.

Intervention type: DRUG
Group type: OTHER
Intervention: one proton pump inhibitor(PPI)
Description: All the patients need this drug.

Intervention type: DRUG
Group type: OTHER
Intervention: one proton pump inhibitor(PPI)
Description: All the patients need this drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal Bismuth Pectin
Description: All the patients treated with 14-day bismuth-based quadruple therapy need this drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Colloidal Bismuth Pectin
Description: All the patients treated with 14-day bismuth-based quadruple therapy need this drug.

Intervention type: DRUG
Group type: OTHER
Intervention: Colloidal Bismuth Pectin
Description: All the patients treated with 14-day bismuth-based quadruple therapy need this drug.

Intervention type: DRUG
Group type: OTHER
Intervention: two antibiotics for failed eradication(tetracyclin,furazolidone)
Description: If the patients failed with AST guided eradication therapy or empirical therapy, patients will be treated with another 14-day bismuth-based quadruple therapy. The regimen contains one PPI, Colloidal Bismuth Pectin, tetracycline and furazolidone.
Study: NCT01810484

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy® treatment only
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy® treatment only
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy® treatment only
Description: Focused ultrasound energy delivered below the surface of the skin

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy® treatment and CO2 laser treatment
Description: Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy® treatment and CO2 laser treatment
Description: Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultherapy® treatment and CO2 laser treatment
Description: Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;~CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Laser treatment only
Description: CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Laser treatment only
Description: CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 Laser treatment only
Description: CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
Study: NCT02217163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib, , Cyclophosphamide, Dexamethasone
Description: Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
Study: NCT03915704

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention was made in the children.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: Buzzy was placed 3-5 cm above the injection site 60 sec before the injection and used until the procedure was completed.The Buzzy application to all children in this group was done by the second researcher. After the injection, the ice pack was wiped with 70% alcohol and frozen again by freezing.
Study: NCT00212160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: omentectomy
Description: RYGB with omentectomy
Study: NCT06302517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS-guided
Description: underwent intraoperative monitoring of BIS anesthesia depth
Study: NCT04133051

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block Using Bupivacaine 0.2%
Description: Ultrasound guided transmuscular approach for quadratus lumborum block using an 18 gauge Touhy's epidural needle to insert the catheter. Normal saline 5 mL will be used to identify that plane. A volume of 20 ml of 0.25% of Bupivacaine bolus will be injected in that plane just over QL. This will be followed by epidural catheter insertion to facilitate continuous infusion. A similar procedure will be performed on the other side. A continuous infusion of 0.2% Bupivacaine at 5 ml/h will be administered to the patient.~This transmuscular quadratus lumborum (TQL) block, has been suggested to be a simple and perhaps safer alternative to the anterior approach as was described for the original QL block
Study: NCT01147042

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN-gamma
Description: Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IFN-gamma
Description: Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
Study: NCT05664321

Intervention type: OTHER
Intervention: Observational, case-control study
Description: obese \[(BMI ≥30 kg/m2), (n=44)\], and non-obese \[(BMI= 18.50-24.99 kg/m2), (n=48)\].

Intervention type: OTHER
Intervention: Observational, case-control study
Description: obese \[(BMI ≥30 kg/m2), (n=44)\], and non-obese \[(BMI= 18.50-24.99 kg/m2), (n=48)\].
Study: NCT00761475

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh supported closure
Description: onlay mesh supported closure midline laparotomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: primary closure
Description: primary closure of the midline

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mesh supported closure
Description: sublay mesh supported closure midline laparotomy
Study: NCT03296917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrEP-001
Description: A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: G-004
Description: A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
Study: NCT04714606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sibling support group
Description: The intervention is a novel, 8 session sibling support group which has been created for the purpose of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: None - control condition
Description: The second arm of the study is a control condition in which participants will be given a tailored booklet to complete at home as it was deemed unethical to provide them with nothing.
Study: NCT04397510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Nebulized Heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: Nebulized 0.9% Sodium Chloride
Study: NCT02389166

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow
Description: Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.~High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional oxygen therapy
Description: Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
Study: NCT03991312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: Participants will receive an oral solution as described in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rifampin
Description: Participants will receive oral capsule(s) as described in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitapivat sulfate
Description: Participants will receive an oral tablet as described in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mitapivat sulfate
Description: Participants will receive an oral tablet as described in the arm description.
Study: NCT03287791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic Azelaic Acid Foam
Description: Topical foam, generic formulation of the brand product.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finacea® (Azelaic Acid) Foam
Description: Topical foam, brand product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Topical foam, placebo. Has no active ingredient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cleanser
Description: A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cleanser
Description: A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cleanser
Description: A mild cleanser provided to participants, so they can wash their face prior to applying the study drug.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen provided to participants, so they can apply it to their face when outdoors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Sunscreen provided to participants, so they can apply it to their face when outdoors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sunscreen
Description: Sunscreen provided to participants, so they can apply it to their face when outdoors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Towel
Description: A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Towel
Description: A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Towel
Description: A soft towel provided to participants, so they can pat their face dry after washing and prior to applying the study drug.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moisturizing Lotion
Description: Moisturizing lotion provided to participants, so they can apply it to their face, as needed.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizing Lotion
Description: Moisturizing lotion provided to participants, so they can apply it to their face, as needed.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Moisturizing Lotion
Description: Moisturizing lotion provided to participants, so they can apply it to their face, as needed.
Study: NCT02701517

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine + METHOTREXATE
Description: MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine + CAMPATH-1H
Description: CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
Study: NCT05971446

Intervention type: DEVICE
Intervention: Visual Evoked Potential (VEP)
Description: Small gold-cup electrodes will be placed on the participant's head using a small dot of adhesive paste. The handheld device is then connected to the electrodes, and the participant's eyes are exposed to a light flicker. Each eye will be tested separately, and while testing one eye, the other eye may be patched.

Intervention type: DEVICE
Intervention: Visual Evoked Potential (VEP)
Description: Small gold-cup electrodes will be placed on the participant's head using a small dot of adhesive paste. The handheld device is then connected to the electrodes, and the participant's eyes are exposed to a light flicker. Each eye will be tested separately, and while testing one eye, the other eye may be patched.

Intervention type: DEVICE
Intervention: Electroretinogram (ERG)
Description: Skin electrodes will be placed under each eye. Eyes will then be exposed to a flashing light. Each eye will be tested separately and while testing one eye, the other eye may be patched.

Intervention type: DEVICE
Intervention: Electroretinogram (ERG)
Description: Skin electrodes will be placed under each eye. Eyes will then be exposed to a flashing light. Each eye will be tested separately and while testing one eye, the other eye may be patched.
Study: NCT02831621

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention (diet OR diet+exercise)
Description: diet or diet+fitness training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention (diet OR diet+exercise)
Description: diet or diet+fitness training
Study: NCT04842903

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic touch is an energy transfer process based on the assumption that every living organism in the universe has an energy field and these energy fields that interact with each other can be changed with the practices made by a conscious and certain intent. TT is an independent nursing practice first applied and developed by nurses Dora Kunz and Dolores Krieger in 1972. TT is also an art of concentration therapy in which the therapist focuses on consciousness as a focus to create balance and coordination in the mutual energy fields of the patient and the environment, and uses their hands to transfer energy. The fact that TT is easy to use, has no known side effects, has low costs, is non-invasive, and its importance among nurses and increasing frequency of its practice in recent years show that it is a powerful alternative to other CAT methods.
Study: NCT04275323

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: NL003
Description: Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
Study: NCT03985241

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Assessment of Myocardial Ischemia by icECG
Study: NCT00811161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airgent
Description: HA needle free injection, 3-4 treatments, 3-4 weeks apart
Study: NCT03088891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antioxidant-rich snacks
Description: Bama Smoothies (Bama, Oslo, Norway), Freia Premium Dark Chocolate (Freia, Oslo, Norway), Walnuts (Eldorado, Norway), Dried fruits and berries (Cranberries, Gojiberries, apricots)(Bama, Oslo, Norway and Rema 1000, Norway)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control snacks
Description: Milkshake (Tine, Oslo, Norway), YT restitusjonsdrikk (Tine, Oslo, Norway), Bixit (Sætre, Oslo, Norway), Ritz (Mondelez, Oslo, Norway), White chololate (Freia, Oslo, Norway)
Study: NCT01840007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Group
Description: The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.~Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken.
Study: NCT04296656

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The 5 S's infant calming intervention
Description: 5 simple steps to calm a fussy or crying infant. Steps include swaddling, side position, sound (white noise), swing and suck.
Study: NCT00675402

Intervention type: OTHER
Intervention: supervised treadmill exercise program
Description: Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
Study: NCT02916966

Intervention type: OTHER
Intervention: Patient Registry
Description: Patient Registry

Intervention type: OTHER
Intervention: Patient Registry
Description: Patient Registry

Intervention type: OTHER
Intervention: Patient Registry
Description: Patient Registry

Intervention type: OTHER
Intervention: Patient Registry
Description: Patient Registry
Study: NCT04416568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Combination Therapy: Nivolumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles.~Monotherapy: Starting with cycle 5 nivolumab at predetermined dosage on day 1 and day 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Combination Therapy: Ipilimumab at predetermined dosage day 1 of a 21-day cycle for 4 cycles
Study: NCT03600272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Description: Combined spinal-epidural analgesia during labor is a labor analgesia technique which reported maybe associate with a shorter labor duration compared to the traditional epidural labor analgesia.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Epidural analgesia
Description: Epidural analgesia is a well-accepted technique using for pain relief during labor.
Study: NCT02171221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral DFP-11207
Study: NCT05261555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NoObesity app
Description: The NoObesity system consists of two linked apps - the NoObesity Family app and the NoObesity Professional app.